PAVmed Inc
NASDAQ:PAVM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
PAVmed Inc
NASDAQ:PAVM
|
US |
|
C
|
CyberAgent Inc
OTC:CYAGF
|
JP |
|
Coda Octopus Group Inc
NASDAQ:CODA
|
US |
|
Witbe SA
PAR:ALWIT
|
FR |
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
DE |
|
Kingsoft Cloud Holdings Ltd
NASDAQ:KC
|
CN |
|
C
|
Changshu Guorui Technology Co Ltd
SZSE:300600
|
CN |
|
Tongtai Machine & Tool Co Ltd
TWSE:4526
|
TW |
|
Jewett-Cameron Trading Company Ltd
NASDAQ:JCTCF
|
US |
|
M
|
MEP Infrastructure Developers Ltd
NSE:MEP
|
IN |
|
Achilles Corp
TSE:5142
|
JP |
|
Consolidated Water Co Ltd
NASDAQ:CWCO
|
KY |
|
I
|
Israel Acquisitions Corp
NASDAQ:ISRL
|
US |
|
Patriot Battery Metals Inc
XTSX:PMET
|
CA |
|
Grupo Pochteca SAB de CV
BMV:POCHTECB
|
MX |
|
B
|
Biomind Labs Inc
NEO:BMND
|
CA |
PAVmed Inc
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. The company is headquartered in New York City, New York and currently employs 89 full-time employees. The company went IPO on 2016-07-27. The firm has four operating divisions. GI Health division includes EsoGuard, EsoCheck and EsoCure. EsoGuard and EsoCheck have been developed to provide non-invasive, patient-friendly screening test for the early detection of adenocarcinoma of the esophagus (EAC) and Barrett's Esophagus (BE), including dysplasia and related pre-cursors to EAC in patients with chronic gastroesophageal reflux (GERD). EsoCure is in development as an Esophageal Ablation Device with the intent to allow a clinician to treat dysplastic BE before it can progress to EAC. Minimally Invasive Interventions division offers CarpX, a minimally invasive surgical device for carpal tunnel syndrome. Infusion Therapy division includes PortIO, which is an implantable, intraosseous vascular access device, and NextFlo, which is a disposable, infusion platform technology that includes intravenous infusion sets and disposable infusion pumps.
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. The company is headquartered in New York City, New York and currently employs 89 full-time employees. The company went IPO on 2016-07-27. The firm has four operating divisions. GI Health division includes EsoGuard, EsoCheck and EsoCure. EsoGuard and EsoCheck have been developed to provide non-invasive, patient-friendly screening test for the early detection of adenocarcinoma of the esophagus (EAC) and Barrett's Esophagus (BE), including dysplasia and related pre-cursors to EAC in patients with chronic gastroesophageal reflux (GERD). EsoCure is in development as an Esophageal Ablation Device with the intent to allow a clinician to treat dysplastic BE before it can progress to EAC. Minimally Invasive Interventions division offers CarpX, a minimally invasive surgical device for carpal tunnel syndrome. Infusion Therapy division includes PortIO, which is an implantable, intraosseous vascular access device, and NextFlo, which is a disposable, infusion platform technology that includes intravenous infusion sets and disposable infusion pumps.
Balance sheet: Management said the February recapitalization and financing removed the legacy convertible securities and left PAVmed with a “clean cap table,” which they believe puts the company on firmer financial footing.
Lucid momentum: Lucid reported fourth-quarter EsoGuard revenue of about $1.5 million and 3,664 tests, up 24% and 29%, respectively, from the third quarter, and it won a U.S. Department of Veterans Affairs contract.
Veris progress: Veris completed full Epic integration with Ohio State University and remains on track for a planned FDA 510(k) submission for its implantable physiologic monitor later this year.
New strategy: PAVmed is relaunching its medical device portfolio, naming Joe Virgilio to lead the effort and advancing both PortIO and a newly licensed Duke endoscopic imaging technology.
Commercial expansion: Management said OSU is targeting at least 1,000 patients in the first year and that broader rollout to other cancer centers will likely wait until after the implantable device is cleared, with added clinical support services seen as important for adoption.
